Pediatrics Strabismus News

SAN FRANCISCO — A low-dose, preservative-free formulation of atropine is effective in slowing myopia progression in children aged 3 to 17 years, according to phase 3 data presented here.

NEW YORK — In this Healio Video Perspective from OSN New York’s Disruptive Innovations Symposium, Nick Ruth of Sydnexis provides an update on a progressive myopia treatment for pediatric patients that is in development.

NEW ORLEANS — Objectively measured accommodative amplitude increased throughout the day in children using low-dose atropine for myopia management, according a study presented at Academy ’23.

This issue’s roundtable from our pediatric ophthalmology colleagues covers two important topics: amblyopia therapy and progressive myopia treatment. Our first challenge is to diagnose these two conditions at an early age.

According to a 2016 analysis of 145 studies including 2.1 million participants, myopia will affect nearly 50% of the global population by 2050.

A study of 40 patients recently published in Cureus suggested that SARS-CoV-2 may be transmissible via ocular routes.

An intervention undertaken by dozens of health centers reduced antibiotic use for pediatric conjunctivitis by up to 19% without increasing treatment failure, according to study findings.

SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Darius M. Moshfeghi, MD, FASRS, discusses the LONGROP study in retinopathy of prematurity.

Before I was in medical school, I spent time volunteering in a hospital emergency room.

Despite developments such as the FDA approval of Eylea, disparities are still present in access to care for retinopathy of prematurity.